Novel Treatments and Approaches in Migraine Research (as of February 2025)
Posted on February 23 2025,
Novel Treatments and Approaches in Migraine Research
Novel Compounds
MTX101 (Bispecific autoimmune checkpoint inhibitor) NCT06728553
MTX-101 is a drug that attaches to two specific receptors on immune system "peace-keeper" cells (CD8 T-regulatory cells), activating them to better perform their function. Once activated, these peace-keeper cells help control autoimmune diseases by eliminating problematic immune cells that are attacking the body's healthy tissues.
BHV-2100 (TRPM3 Antagonist) NCT06603623
BHV-2100 is an experimental pain medication that works in a completely new way - it blocks a specific protein (TRPM3) found on pain-sensing nerve cells. In lab tests and animal studies, the drug effectively reduced different types of pain, particularly nerve pain, without causing common side effects like drowsiness or changes in body temperature, suggesting it could potentially become a new treatment option for chronic pain conditions in humans if clinical trials are successful.
MEDI0618 (proteinase-activated receptor-2 modulator) NCT06602479
MEDI0618 is a drug that works by regulating a specific protein receptor (called PAR-2) that's involved in pain and inflammation. It's being developed by AstraZeneca as a potential treatment for both migraine headaches and long-term joint pain caused by osteoarthritis.
Lu AG09222 (PACAP Receptor Antibody) NCT06578585
A novel monoclonal antibody therapeutic targeting the PAC1 receptor, being studied both as a standalone treatment and in combination with ubrogepant for migraine management. Represents a new mechanism of action distinct from CGRP-targeted therapies.
IPN10200 (Neurotoxin) NCT06625060
A new injectable neuromodulating medication designed to be administered directly into head and neck muscles for migraine prevention. May work similarly to other neurotoxin treatments by inhibiting release of pain neurotransmitters.
JS010 (Anti-CGRP Monoclonal Antibody) NCT06158737
A phase I trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of JS010, a monoclonal antibody targeting CGRP, in healthy subjects.
Psilocybin NCT04218539
Investigating the efficacy of single and repeated dosing of psilocybin for migraine treatment, including measurement of neuroinflammatory markers. (Novel due to not being approved for any medical uses).
AGX-201 (Histamine Dihydrochloride) NCT02021474
Evaluating the efficacy and safety of subcutaneous AGX-201 for migraine prophylaxis by targeting histamine type 3 receptors to reduce neuroinflammation.
UB-313 (Anti-CGRP Immunotherapeutic) NCT05477095
A phase I trial evaluating the safety, tolerability, and immunogenicity of UB-313, an anti-CGRP immunotherapeutic candidate, in healthy participants.
Novel Approaches
Localized Meningeal Injection NCT06462781
Innovative approach using targeted injection of lidocaine and steroids into middle meningeal arteries for chronic migraine treatment.
Remote Electrical Neuromodulation for Pediatric Migraine NCT05102591
Development of a new neuromodulation device specifically designed for acute migraine attacks in children and adolescents.
Migraine Manager (Behavioral Intervention) NCT04567355
A randomized clinical trial testing whether an online tailored intervention, Migraine Manager, is efficacious in improving headache outcomes compared to an attention control intervention in adolescents with migraines.
Biofeedback-Assisted Relaxation Training (BART) NCT03472092
A behavioral intervention assessing the impact of biofeedback-assisted relaxation training on headache outcomes in youth with migraine.
Cognitive Reappraisal Training (CR) NCT03472092
A behavioral approach examining cognitive reappraisal training as a preventive measure for migraine in youth.
Aerobic Training NCT05741775
A randomized trial analyzing the effectiveness of aerobic exercise on resting-state brainwaves and quality of life in university students with migraine symptoms.
Biofeedback Training NCT05741775
A non-drug intervention evaluating biofeedback training's impact on sleep quality and migraine disability in university students with migraine symptoms.
New Applications of Existing Medications
Atorvastatin for Migraine Prevention NCT06485336
Investigating the use of this common cholesterol medication at different doses (20 mg and 40 mg) for migraine prevention, based on promising results from earlier studies.
Tizanidine for Episodic Migraine NCT05484349
Evaluating this muscle relaxant's potential as a preventive treatment for episodic migraine in adults.
Intranasal Ketorolac NCT06083571
Novel delivery method of this established NSAID, investigating its efficacy when administered intranasally compared to traditional intravenous administration.
Anisodine Hydrobromide NCT05416476
Repurposing this anticholinergic agent for the preventive treatment of episodic migraine in adults.
High-Flow Oxygen Therapy NCT04925414
Investigating the use of normobaric oxygen therapy for acute migraine attacks, based on its success in cluster headaches and emerging understanding of migraine pathophysiology.
Candesartan for Migraine Prevention NCT04574713
Assessing the efficacy of candesartan, an angiotensin II receptor blocker, as a preventive treatment for episodic migraine.
Nicotinic Acid (Niacin) for Migraine NCT05846373
Studying the efficacy of nicotinic acid as a prophylactic agent for moderate to severe migraine, potentially through increasing serotonin levels and anti-inflammatory effects.
Intranasal Oxytocin (TNX-1900) NCT05679908
Evaluating the efficacy and safety of two dosages of intranasal oxytocin for the prevention of chronic migraine, based on its ability to block CGRP release.
Valproic Acid vs Propranolol for Migraine Prevention NCT06485726
A trial comparing the effect of valproic acid versus propranolol in reducing monthly migraine days in patients with migraine disorders.
Lacosamide vs Topiramate for Migraine Prevention NCT06243692
A randomized trial comparing the effect of lacosamide versus topiramate in migraine by assessing the reduction in monthly migraine days.
Ethinylestradiol/levonorgestrel for Migraine Prevention NCT04007874
An open-label trial studying the efficacy of continuous ethinylestradiol/levonorgestrel compared with vitamin E in women with menstrually-related and perimenopausal migraine.
Eptinezumab in Emergency Context NCT06428838
A trial investigating eptinezumab as an adjunct to standard care for migraine in an acute emergency setting to prevent migraine recurrence.
Zonisamide vs Topiramate for Migraine Prevention NCT06347497
A trial comparing the effect of zonisamide versus topiramate in reducing monthly migraine days in patients with migraine.
Amitriptyline w/ Behavioral Intervention for Migraine Prevention NCT03472092
A randomized trial evaluating amitriptyline's efficacy in reducing headache days in youth with migraine, alongside behavioral interventions.
Rimegepant in Adolescents NCT06616194
A study evaluating rimegepant's effect in adolescents with frequent migraine attacks, assessing reduction in monthly migraine days.
Flunarizine vs 1st Line Meds for Migraine Prevention NCT06499116
A multicenter trial comparing flunarizine with other first-line preventive treatments for migraine, assessing reduction in monthly migraine days.
Atogepant in Japanese Participants NCT05861427
A study assessing atogepant's safety and efficacy in reducing migraine symptoms in adult Japanese participants with episodic migraine.
Zolmitriptan for Migraine Prophylaxis NCT06089356
A trial evaluating zolmitriptan as a prophylactic therapy for childhood migraine, comparing with topiramate and valproate.
Ubrogepant for Menstrual Migraine NCT06417775
A study assessing ubrogepant's safety and efficacy in treating menstrual migraine, focusing on adverse events and change in disease activity.
Botulinum Toxin Type A (Dysport) for Episodic Migraine NCT04069897
A trial assessing the efficacy of botulinum toxin type A injection into the sphenopalatine ganglion for treatment-refractory chronic migraine.
Cannabidiol (CBD) for Migraine Prophylaxis NCT03972124
A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of cannabis (CBD) for the treatment of chronic migraine headaches.
Naltrexone w/ Acetaminophen for Migraine Treatment NCT05685225
A two-stage trial assessing the efficacy of naltrexone combined with acetaminophen for the acute treatment of migraine, focusing on pain freedom.
Paroxetine for Tinnitus-Related Migraine NCT06799169
A trial evaluating paroxetine's potential in reducing the impact of tinnitus-related migraine symptoms, assessing changes in tinnitus functional index.
Verapamil for Tinnitus-Related Migraine NCT06799169
A trial evaluating verapamil's potential in reducing the impact of tinnitus-related migraine symptoms, assessing changes in tinnitus functional index.
Pizotifen for Migraine Prophylaxis NCT06158230
A trial comparing the efficacy and adverse effects of pizotifen versus a combination of amitriptyline-propranolol for migraine prophylaxis.
Zavegepant w/ Anti-CGRP Preventives for Acute Migraine Treatment NCT06401642
A study evaluating the effectiveness and tolerability of zavegepant for acute migraine treatment among participants using CGRP-targeting preventive medications.
Tenoxicam vs Ibuprofen for Acute Migraine Attack NCT06786650
A trial comparing the analgesic effects of intravenous tenoxicam versus ibuprofen in acute migraine attacks, assessing pain palliation.
Nortriptyline for Meniere's-Related Migraine NCT05582837
A trial evaluating nortriptyline's potential in improving Meniere's disease-related migraine symptoms, assessing subjective improvement.
Ketamine for Chronic Daily Headache NCT05306899
A multicenter trial assessing the efficacy and safety of high-dose intravenous ketamine infusions compared to saline in participants with chronic daily headaches.
Metoprolol for Migraine with PFO NCT05546320
A trial comparing metoprolol's efficacy with other medications in alleviating migraine symptoms in patients with patent foramen ovale.
Rivaroxaban for Migraine with PFO NCT05546320
A trial evaluating rivaroxaban's efficacy in alleviating migraine symptoms in patients with patent foramen ovale, focusing on responder rate.
Thu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read MoreWed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read More